Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol measurement in Familial Dysbetalipoproteinemia

Publication date

2023-01-15

Authors

Heidemann, Britt E.
Koopal, C.
Roeters van Lennep, Jeanine E.
Stroes, Erik S.
Riksen, Niels P.
Mulder, Monique T.
van Vark – van der Zee, Leonie C.
Blackhurst, Dee M.
Visseren, Frank L.J.ISNI 0000000389493675
Marais, A. David

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Aim: To compare LDL-C concentrations using the Friedewald formula, the Martin-Hopkins formula, a direct assay and polyacrylamide gradient gel electrophoresis (PGGE) to the reference standard density gradient ultracentrifugation in patients with Familial Dysbetalipoproteinemia (FD) patients. We also compared non-HDL-cholesterol concentrations by two methods. Methods: For this study data from 28 patients with genetically confirmed FD from the placebo arm of the EVOLVE-FD trial were used. Four different methods for determining LDL-C were compared with ultracentrifugation. Non-HDL-C was measured with standard assays and compared to ultracentrifugation. Correlation coefficients and Bland-Altman plots were used to compare the methods. Results: Mean age of the 28 FD patients was 62 ± 9 years, 43 % were female and 93 % had an ɛ2ɛ2 genotype. LDL-C determined by Friedewald (R2 = 0.62, p <0.01), Martin-Hopkins (R2 = 0.50, p = 0.01) and the direct assay (R2 = 0.41, p = 0.03) correlated with density gradient ultracentrifugation. However, Bland-Altman plots showed considerable over- or underestimation by the four methods compared to ultracentrifugation. Non-HDL-C showed good correlation and agreement. Conclusion: In patients with FD, all four methods investigated over- or underestimated LDL-C concentrations compared with ultracentrifugation. In contrast, standard non-HDL-C assays performed well, emphasizing the use of non-HDL-C in patients with FD.

Keywords

Aged, Cholesterol, Cholesterol, HDL, Cholesterol, LDL, Female, Humans, Hyperlipoproteinemia Type III/drug therapy, Lipoproteins, Male, Middle Aged, Triglycerides, Martin-Hopkins, Polyacrylamide gels, FRIEDEWALD, Treatment goal, Familial Dysbetalipoproteinemia, Direct homogeneous assay, Low-density lipoprotein, Non-high-density lipoprotein, Density gradient ultracentrifugation, Type III hyperlipoproteinemia, Biochemistry, medical, Biochemistry, Clinical Biochemistry, Journal Article

Citation

Heidemann, B E, Koopal, C, Roeters van Lennep, J E, Stroes, E S, Riksen, N P, Mulder, M T, van Vark – van der Zee, L C, Blackhurst, D M, Visseren, F L J & Marais, A D 2023, 'Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol measurement in Familial Dysbetalipoproteinemia', Clinica Chimica Acta, vol. 539, pp. 114-121. https://doi.org/10.1016/j.cca.2022.11.035